PFE: 84/100 - Strong uptrend and high volume breakout confirmation, but overbought RSI caps the score.
MRK: 10/100 - No actionable setup; extreme overbought condition and poor reward:risk.
MA: 89/100 - Best setup: clear uptrend, tight stop at support, high reward:risk with positive accumulation.
TSLA: 63/100 - Counter-trend trade with weak volume confirmation and conflicting technical signals.
COCOA: 20/100 - Mixed trend, poor risk/reward, and low conviction; no trade.
PLTR: 75/100 - Bullish structure but declining momentum and weak volume confirmation.
CVX: 84/100 - Solid uptrend and accumulation, yet overbought conditions on entry.
XAGUSD: 70/100 - Bullish trend but negative CMF and resistance overhead reduce confidence.
ADBE: 69/100 - Uptrend intact but mixed momentum and overbought short-term conditions.
Overall winner: MA (89/100)
PFE BUY
Direction: BUY
Entry: $28.45 (limit)
Stop Loss: $27.86
Take Profit 1: $29.63 (+4.1%)
Take Profit 2: $31.00 (+9.0%)
R:R: 2.0
Position Size: 1.5% of account
Confidence: 70/100
Holding Period: 10 days
Key Levels
- Resistance: $28.44, $28.75
- Support: $27.00, $26.50
Rationale
PFE is in a bullish macro trend, trading above all major moving averages with strong momentum (ADX 38, MACD rising, OBV up). The stock is pressing against a key resistance at 28.44 (10-day high) with high volume on the last up day (RVOL 1.47x), suggesting a potential breakout. Earnings are on Nov 3, 2026, far outside the 10-day holding window, eliminating gap risk. A buy stop above 28.45 triggers entry on continuation; stop is placed at 1x ATR (0.59) to manage volatility while keeping the trade aligned with the uptrend. Reward/risk at TP1 is 2:1, and TP2 offers further upside, supported by bullish analyst targets and recent Q2 earnings beat.
Risks
- RSI 14 at 77.4 is overbought, increasing the risk of a short-term pullback.
- Price is near the 52-week high (28.75), which could act as resistance.
- The stock has been consolidating; a false breakout might trigger the stop.
- General market volatility (VIX 15.27) and sector-specific news could affect price.
News Summary
Pfizer's Q2 2026 earnings beat expectations, with EPS $0.77 vs $0.68 estimate and revenue $15.03B vs $14.39B, leading to a raised revenue guidance. Positively, the EMA validated Valneva's Lyme disease vaccine candidate. Analysts are optimistic with price targets averaging $28.51 (current ~$28.24). No earnings within the 10-day window (next report Nov 3, 2026). tradingview.com, barchart.com, google.com/finance
{
"ticker": "PFE",
"direction": "LONG",
"entry_price": 28.45,
"stop_loss": 27.86,
"take_profit_1": 29.63,
"take_profit_2": 31.0,
"reward_risk_ratio": 2.05,
"position_size_pct": 1.5,
"confidence": 70,
"holding_period_days": 10,
"key_levels": {
"support": [
27.0,
26.5
],
"resistance": [
28.44,
28.75
]
},
"rationale": "PFE is in a bullish macro trend, trading above all major moving averages with strong momentum (ADX 38, MACD rising, OBV up). The stock is pressing against a key resistance at 28.44 (10-day high) with high volume on the last up day (RVOL 1.47x), suggesting a potential breakout. Earnings are on Nov 3, 2026, far outside the 10-day holding window, eliminating gap risk. A buy stop above 28.45 triggers entry on continuation; stop is placed at 1x ATR (0.59) to manage volatility while keeping the trade aligned with the uptrend. Reward/risk at TP1 is 2:1, and TP2 offers further upside, supported by bullish analyst targets and recent Q2 earnings beat.",
"risks": [
"RSI 14 at 77.4 is overbought, increasing the risk of a short-term pullback.",
"Price is near the 52-week high (28.75), which could act as resistance.",
"The stock has been consolidating; a false breakout might trigger the stop.",
"General market volatility (VIX 15.27) and sector-specific news could affect price."
],
"news_summary": "Pfizer's Q2 2026 earnings beat expectations, with EPS $0.77 vs $0.68 estimate and revenue $15.03B vs $14.39B, leading to a raised revenue guidance. Positively, the EMA validated Valneva's Lyme disease vaccine candidate. Analysts are optimistic with price targets averaging $28.51 (current ~$28.24). No earnings within the 10-day window (next report Nov 3, 2026). [tradingview.com](https://www.tradingview.com/symbols/NYSE-PFE/), [barchart.com](https://www.barchart.com/stocks/quotes/pfe), [google.com/finance](https://www.google.com/finance/quote/PFE:NYSE)"
}
MRK
Confidence: 85/100
Key Levels
- Resistance: $153.50
- Support: $126.68, $126.22, $111.57
Rationale
Despite a strong uptrend and positive momentum, MRK is extremely overbought after a 12.6% gap-up on 2026-08-19, with RSI at 83.2 and price above the upper Bollinger Band. The stock is 34% above its 200-day SMA and extended versus its moving averages. Technical sources indicate no decent entry at current levels and advise waiting for consolidation (see chartmill.com). A stop-loss within 1.5×ATR (≈$6.48) would be placed around $145.72, while a 2:1 reward:risk target would be above $165, which is unsupported by recent levels. The weekly RSI at 75 also flags overbought conditions. Thus, no acceptable risk/reward setup exists for a 10-day holding period.
Risks
- Extreme overbought conditions could lead to a sharp pullback, making a long entry vulnerable.
- Momentum may persist, but chasing a +12% gap carries high mean-reversion risk.
- The stock is trading far above key support levels, increasing uncertainty for stop placement.
- Potential profit-taking or news-driven volatility could cause adverse price moves.
News Summary
Merck's next earnings date is 2026-10-29, well outside the 10-day holding window, so no earnings gap risk (source: barchart.com). The recent surge appears linked to positive trial results for sacituzumab tirumotecan in endometrial cancer (source: trendspider.com). However, technical analysis from chartmill.com notes that while the stock has excellent long-term ratings, it does not present a decent entry opportunity at this time, and waiting for consolidation is advisable. Analyst consensus remains a 'Moderate Buy' with a price target implying limited upside from current levels (source: barchart.com).
{
"ticker": "MRK",
"direction": "NO_TRADE",
"entry_price": null,
"stop_loss": null,
"take_profit_1": null,
"take_profit_2": null,
"reward_risk_ratio": null,
"position_size_pct": null,
"confidence": 85,
"holding_period_days": null,
"key_levels": {
"support": [
126.68,
126.22,
111.57
],
"resistance": [
153.5
]
},
"rationale": "Despite a strong uptrend and positive momentum, MRK is extremely overbought after a 12.6% gap-up on 2026-08-19, with RSI at 83.2 and price above the upper Bollinger Band. The stock is 34% above its 200-day SMA and extended versus its moving averages. Technical sources indicate no decent entry at current levels and advise waiting for consolidation (see [chartmill.com](https://www.chartmill.com/stock/quote/MRK/technical-analysis)). A stop-loss within 1.5×ATR (≈$6.48) would be placed around $145.72, while a 2:1 reward:risk target would be above $165, which is unsupported by recent levels. The weekly RSI at 75 also flags overbought conditions. Thus, no acceptable risk/reward setup exists for a 10-day holding period.",
"risks": [
"Extreme overbought conditions could lead to a sharp pullback, making a long entry vulnerable.",
"Momentum may persist, but chasing a +12% gap carries high mean-reversion risk.",
"The stock is trading far above key support levels, increasing uncertainty for stop placement.",
"Potential profit-taking or news-driven volatility could cause adverse price moves."
],
"news_summary": "Merck's next earnings date is 2026-10-29, well outside the 10-day holding window, so no earnings gap risk (source: [barchart.com](https://www.barchart.com/stocks/quotes/mrk)). The recent surge appears linked to positive trial results for sacituzumab tirumotecan in endometrial cancer (source: [trendspider.com](https://trendspider.com/markets/symbols/MRK/)). However, technical analysis from [chartmill.com](https://www.chartmill.com/stock/quote/MRK/technical-analysis) notes that while the stock has excellent long-term ratings, it does not present a decent entry opportunity at this time, and waiting for consolidation is advisable. Analyst consensus remains a 'Moderate Buy' with a price target implying limited upside from current levels (source: [barchart.com](https://www.barchart.com/stocks/quotes/mrk))."
}
MA BUY
Direction: BUY
Entry: $561.50 (limit)
Stop Loss: $556.00
Take Profit 1: $582.50 (+3.7%)
Take Profit 2: $590.00 (+5.1%)
R:R: 3.8
Position Size: 1.0% of account
Confidence: 70/100
Holding Period: 10 days
Key Levels
- Resistance: $582.93, $583.71
- Support: $556.00, $560.00
Rationale
Daily trend is consolidating but price remains above the 200 SMA (526.69) and Supertrend is UP. ADX 33 indicates a strong underlying trend, while recent pullback to the EMA21 (560.61) and 10-day low (556.06) provides a favorable long entry with a tight stop. Resistance at 582.93 offers a clear target with a risk/reward greater than 3:1. CMF 0.14 confirms accumulation, and the next earnings date is far outside the 10-day window.
Risks
- A decisive break below 556.00 would invalidate the long setup and could trigger further downside toward the 20-day support at 523.61.
- VIX at 15.19 is moderate but a spike in volatility could lead to wider-than-expected swings, potentially hitting the stop.
- Consolidation near all-time highs may persist longer than expected, delaying the move toward resistance within the 10-day horizon.
News Summary
Next earnings date is 2026-10-29, well outside the 10-day holding period; no earnings gap risk. Recent news shows no major company-specific catalysts. The broader market remains bullish, with SPY trading 9.2% above its 200-day SMA. MA's last daily bar closed -0.1% after a 2.1% surge on 2026-08-18, reflecting normal consolidation.
{
"ticker": "MA",
"direction": "LONG",
"entry_price": 561.5,
"stop_loss": 556.0,
"take_profit_1": 582.5,
"take_profit_2": 590.0,
"reward_risk_ratio": 3.82,
"position_size_pct": 1.0,
"confidence": 70,
"holding_period_days": 10,
"key_levels": {
"support": [
556.0,
560.0
],
"resistance": [
582.93,
583.71
]
},
"rationale": "Daily trend is consolidating but price remains above the 200 SMA (526.69) and Supertrend is UP. ADX 33 indicates a strong underlying trend, while recent pullback to the EMA21 (560.61) and 10-day low (556.06) provides a favorable long entry with a tight stop. Resistance at 582.93 offers a clear target with a risk/reward greater than 3:1. CMF 0.14 confirms accumulation, and the next earnings date is far outside the 10-day window.",
"risks": [
"A decisive break below 556.00 would invalidate the long setup and could trigger further downside toward the 20-day support at 523.61.",
"VIX at 15.19 is moderate but a spike in volatility could lead to wider-than-expected swings, potentially hitting the stop.",
"Consolidation near all-time highs may persist longer than expected, delaying the move toward resistance within the 10-day horizon."
],
"news_summary": "Next earnings date is 2026-10-29, well outside the 10-day holding period; no earnings gap risk. Recent news shows no major company-specific catalysts. The broader market remains bullish, with SPY trading 9.2% above its 200-day SMA. MA's last daily bar closed -0.1% after a 2.1% surge on 2026-08-18, reflecting normal consolidation."
}
TSLA BUY
Direction: BUY
Entry: $352.50 (limit)
Stop Loss: $337.00
Take Profit 1: $386.61 (+9.7%)
Take Profit 2: $421.88 (+19.7%)
R:R: 2.2
Position Size: 1.0% of account
Confidence: 55/100
Holding Period: 10 days
Key Levels
- Resistance: $351.62, $356.59, $362.07, $368.60, $386.61
- Support: $340.67, $337.00, $330.23, $324.75
Rationale
TSLA is testing immediate resistance at 351.62 after a +4.2% day. A buy-stop above this level triggers a short-term breakout. Weekly price action shows a bullish hammer/reversal from the 297 support per FXEmpire, and daily MACD histogram is rising with RSI crossing above 50. Earnings are not until 10/28/26 (Barchart), so gap risk is low within the 10-day window. Stop is placed below the 10 EMA and 340.67 support, giving ~1.16x ATR risk. First target 386.61 aligns with FXEmpire's upside objective and provides >2:1 reward/risk. Trade is only valid if the breakout above 351.62 is confirmed on volume.
Risks
- Price is at the upper Bollinger Band and 10-day range high; 1H RSI is 72.3, so short-term overbought conditions could cause a pullback.
- Daily trend is still below the 200 and 50 SMAs with Supertrend down; this is not a confirmed trend reversal yet.
- The latest up day had below-average volume (0.93x RVOL), so breakout confirmation is critical.
- Barchart technical opinion is 88% Sell, conflicting with the bullish reversal setup.
- If price breaks back below 340.67 and the 10 EMA, the trade fails; stop at 337.00.
News Summary
Next earnings are 10/28/26, outside the 10-day holding window, so gap risk is low. FXEmpire highlights a weekly bullish reversal from $297 support with upside targets at $368.60 and $386.61. Barchart shows resistance at $356.59 and support at $340.67, with analyst consensus Moderate Buy but technical opinion rated 88% Sell.
{
"ticker": "TSLA",
"direction": "LONG",
"entry_price": 352.5,
"stop_loss": 337.0,
"take_profit_1": 386.61,
"take_profit_2": 421.88,
"reward_risk_ratio": 2.2,
"position_size_pct": 1.0,
"confidence": 55,
"holding_period_days": 10,
"key_levels": {
"support": [
340.67,
337.0,
330.23,
324.75
],
"resistance": [
351.62,
356.59,
362.07,
368.6,
386.61
]
},
"rationale": "TSLA is testing immediate resistance at 351.62 after a +4.2% day. A buy-stop above this level triggers a short-term breakout. Weekly price action shows a bullish hammer/reversal from the 297 support per [FXEmpire](https://www.fxempire.com/forecasts/article/tesla-inc-tsla-price-forecast-bullish-reversal-targets-386-61-1615090), and daily MACD histogram is rising with RSI crossing above 50. Earnings are not until 10/28/26 ([Barchart](https://www.barchart.com/stocks/quotes/TSLA/overview)), so gap risk is low within the 10-day window. Stop is placed below the 10 EMA and 340.67 support, giving ~1.16x ATR risk. First target 386.61 aligns with FXEmpire's upside objective and provides >2:1 reward/risk. Trade is only valid if the breakout above 351.62 is confirmed on volume.",
"risks": [
"Price is at the upper Bollinger Band and 10-day range high; 1H RSI is 72.3, so short-term overbought conditions could cause a pullback.",
"Daily trend is still below the 200 and 50 SMAs with Supertrend down; this is not a confirmed trend reversal yet.",
"The latest up day had below-average volume (0.93x RVOL), so breakout confirmation is critical.",
"Barchart technical opinion is 88% Sell, conflicting with the bullish reversal setup.",
"If price breaks back below 340.67 and the 10 EMA, the trade fails; stop at 337.00."
],
"news_summary": "Next earnings are 10/28/26, outside the 10-day holding window, so gap risk is low. FXEmpire highlights a weekly bullish reversal from $297 support with upside targets at $368.60 and $386.61. Barchart shows resistance at $356.59 and support at $340.67, with analyst consensus Moderate Buy but technical opinion rated 88% Sell."
}
COCOA
Confidence: 15/100
Key Levels
- Resistance: $6,129.00, $6,222.00, $6,309.00
- Support: $5,425.00, $4,992.00, $3,694.00
Rationale
Daily trend is mixed/consolidating with price below the 9 EMA and MACD histogram falling. Recent price action shows a sharp -3.9% decline on very low volume (RVOL 0.15x) after a failed rally attempt. The 1-hour RSI is 37.4 with StochRSI near oversold, but price remains below VWAP, suggesting short-term weakness. The nearest support is at 5425 (10d) and resistance at 6129 (10d), giving a narrow range. A long entry would require a stop below support, risking over 7%, while a short entry would risk over 5.5% to resistance, and in both cases the potential reward/risk ratio is far below the required 2:1. With no confirmed reversal setup and low conviction, no trade is justified.
Risks
- High volatility (ATR 5.11% of price) could trigger stops quickly.
- MACD histogram falling and RSI below 50 signal bearish momentum.
- Price gapped down -2.3% today, indicating bearish sentiment.
- No earnings catalyst for a futures contract, but sudden fundamental news (weather, supply) could cause erratic moves.
- Support at 5425 may break, leading to further downside.
News Summary
Web search returned results for Chemours (NYSE: CC), not for cocoa futures (CC=F). The search confirmed Chemours' Q2 earnings on Aug 4, 2026, with an EPS miss of -14.06% and a recent stock decline to $14.59. No relevant news was found for CC=F. Since futures have no earnings date, the next earnings field is N/A. The technical data provided for CC=F shows a consolidating market with no clear directional bias.
{
"ticker": "CC=F",
"direction": "NO_TRADE",
"entry_price": null,
"stop_loss": null,
"take_profit_1": null,
"take_profit_2": null,
"reward_risk_ratio": null,
"position_size_pct": null,
"confidence": 15,
"holding_period_days": null,
"key_levels": {
"support": [
5425,
4992,
3694
],
"resistance": [
6129,
6222,
6309
]
},
"rationale": "Daily trend is mixed/consolidating with price below the 9 EMA and MACD histogram falling. Recent price action shows a sharp -3.9% decline on very low volume (RVOL 0.15x) after a failed rally attempt. The 1-hour RSI is 37.4 with StochRSI near oversold, but price remains below VWAP, suggesting short-term weakness. The nearest support is at 5425 (10d) and resistance at 6129 (10d), giving a narrow range. A long entry would require a stop below support, risking over 7%, while a short entry would risk over 5.5% to resistance, and in both cases the potential reward/risk ratio is far below the required 2:1. With no confirmed reversal setup and low conviction, no trade is justified.",
"risks": [
"High volatility (ATR 5.11% of price) could trigger stops quickly.",
"MACD histogram falling and RSI below 50 signal bearish momentum.",
"Price gapped down -2.3% today, indicating bearish sentiment.",
"No earnings catalyst for a futures contract, but sudden fundamental news (weather, supply) could cause erratic moves.",
"Support at 5425 may break, leading to further downside."
],
"news_summary": "Web search returned results for Chemours (NYSE: CC), not for cocoa futures (CC=F). The search confirmed Chemours' Q2 earnings on Aug 4, 2026, with an EPS miss of -14.06% and a recent stock decline to $14.59. No relevant news was found for CC=F. Since futures have no earnings date, the next earnings field is N/A. The technical data provided for CC=F shows a consolidating market with no clear directional bias."
}
PLTR BUY
Direction: BUY
Entry: $174.00 (limit)
Stop Loss: $170.90
Take Profit 1: $180.20 (+3.6%)
Take Profit 2: $183.15 (+5.3%)
R:R: 2.0
Position Size: 1.0% of account
Confidence: 60/100
Holding Period: 10 days
Key Levels
- Resistance: $180.18, $183.15, $196.32
- Support: $171.04, $168.94, $166.32
Rationale
Daily structure remains above key MAs (200 SMA 151.77, EMAs 145.64/157.35/169.55) and Supertrend is UP, while SPY regime is bullish. However, momentum is mixed: ADX 30.8, MACD histogram falling, OBV declining, and price is at 82% of the 10-day range just below 180.18 resistance. A limit buy on a pullback to 174.00 gives a controlled entry with stop below near-term support 171.04 (and 168.94 below), first target 180.20 ($2.0R), and second target 183.15. Next earnings 2026-11-02 is outside the 10-day window, so earnings-gap risk is low. tradersunion.com notes mixed momentum and a $168.94-$179.28 range; tradingkey.com highlights $171.04 support and $183.15 resistance.
Risks
- Limit entry at 174.00 may not fill if price rallies without a pullback.
- Break below 171.04/168.94 would invalidate the long; deeper support at 166.32.
- Low RVOL and falling OBV suggest the breakout above 180.18 may lack volume.
- RSI/StochRSI are near overbought and MACD histogram is falling; consolidation or short-term pullback possible.
- Macro/VIX headline risk remains despite no earnings gap before 2026-11-02.
News Summary
Palantir reported Q2 2026 EPS of $0.41 vs $0.33 expected, with strong revenue growth, and announced a Mercury Systems agreement. Next earnings is 2026-11-02, outside the 10-day holding window. Current technical coverage shows resistance around 180.18/183.15 and support at 171.04/168.94. tradersunion.com tradingkey.com
{
"ticker": "PLTR",
"direction": "LONG",
"entry_price": 174.0,
"stop_loss": 170.9,
"take_profit_1": 180.2,
"take_profit_2": 183.15,
"reward_risk_ratio": 2.0,
"position_size_pct": 1.0,
"confidence": 60,
"holding_period_days": 10,
"key_levels": {
"support": [
171.04,
168.94,
166.32
],
"resistance": [
180.18,
183.15,
196.32
]
},
"rationale": "Daily structure remains above key MAs (200 SMA 151.77, EMAs 145.64/157.35/169.55) and Supertrend is UP, while SPY regime is bullish. However, momentum is mixed: ADX 30.8, MACD histogram falling, OBV declining, and price is at 82% of the 10-day range just below 180.18 resistance. A limit buy on a pullback to 174.00 gives a controlled entry with stop below near-term support 171.04 (and 168.94 below), first target 180.20 ($2.0R), and second target 183.15. Next earnings 2026-11-02 is outside the 10-day window, so earnings-gap risk is low. [tradersunion.com](https://tradersunion.com/news/stocks/show/3023389-palantir-drops-0-97percent-to-usd172-33/) notes mixed momentum and a $168.94-$179.28 range; [tradingkey.com](https://www.tradingkey.com/analysis/stocks/us-stocks/262093276-palantir-pltr-extended-breakout-177-183-overbought-asian-session-tradingkey) highlights $171.04 support and $183.15 resistance.",
"risks": [
"Limit entry at 174.00 may not fill if price rallies without a pullback.",
"Break below 171.04/168.94 would invalidate the long; deeper support at 166.32.",
"Low RVOL and falling OBV suggest the breakout above 180.18 may lack volume.",
"RSI/StochRSI are near overbought and MACD histogram is falling; consolidation or short-term pullback possible.",
"Macro/VIX headline risk remains despite no earnings gap before 2026-11-02."
],
"news_summary": "Palantir reported Q2 2026 EPS of $0.41 vs $0.33 expected, with strong revenue growth, and announced a Mercury Systems agreement. Next earnings is 2026-11-02, outside the 10-day holding window. Current technical coverage shows resistance around 180.18/183.15 and support at 171.04/168.94. [tradersunion.com](https://tradersunion.com/news/stocks/show/3023389-palantir-drops-0-97percent-to-usd172-33/) [tradingkey.com](https://www.tradingkey.com/analysis/stocks/us-stocks/262093276-palantir-pltr-extended-breakout-177-183-overbought-asian-session-tradingkey)"
}
CVX BUY
Direction: BUY
Entry: $200.50 (limit)
Stop Loss: $194.20
Take Profit 1: $213.50 (+6.5%)
Take Profit 2: $218.50 (+9.0%)
R:R: 2.1
Position Size: 1.5% of account
Confidence: 60/100
Holding Period: 10 days
Key Levels
- Resistance: $207.68, $208.92, $213.50
- Support: $200.08, $198.48, $193.22
Rationale
Daily structure is bullish: price is above the 200 SMA and all EMAs, Supertrend is up, ADX=26 confirms trend strength, MACD histogram is rising, and OBV/CMF show accumulation. However, RSI=71.3 and %B=1.04 indicate overbought conditions, and price sits only 0.9% below resistance at 207.68. Chasing here is poor risk/reward. The plan uses a limit entry on a pullback to the 200.50 support zone, validated by the web-derived 200.08 volatility-band support and the Aug 17 close at 200.95. Stop at 194.20 is below nearby structural support, and the first target at 213.50 is the next confirmed overhead resistance, giving roughly 2.1R. Earnings are on Oct 30, 2026, well outside the 10-day holding window, so gap risk from earnings is low.
Risks
- Daily RSI is overbought and price is above the upper Bollinger Band, increasing pullback risk.
- A break below the 200.08 support would invalidate the bull case and may accelerate selling.
- The stock may not pull back to the 200.50 entry within 10 days, causing the trade to be missed.
- Energy sector volatility and crude oil price swings could adversely affect CVX.
- Broader market weakness or a rise in VIX could pressure the stock despite its strong chart.
News Summary
Verification via web search confirms strong bullish news: CVX posted a 287% jump in Q2 2026 adjusted earnings to $12 billion, achieved production records, and is positioned to benefit from Hess synergies. BlackRock also increased its stake. The next earnings report is scheduled around Oct 29-30, 2026, outside the 10-day holding window, so no imminent earnings gap risk. Sources: cryptonomist.ch, tradersunion.com, dragonflycap.com.
{
"ticker": "CVX",
"direction": "LONG",
"entry_price": 200.5,
"stop_loss": 194.2,
"take_profit_1": 213.5,
"take_profit_2": 218.5,
"reward_risk_ratio": 2.06,
"position_size_pct": 1.5,
"confidence": 60,
"holding_period_days": 10,
"key_levels": {
"support": [
200.08,
198.48,
193.22
],
"resistance": [
207.68,
208.92,
213.5
]
},
"rationale": "Daily structure is bullish: price is above the 200 SMA and all EMAs, Supertrend is up, ADX=26 confirms trend strength, MACD histogram is rising, and OBV/CMF show accumulation. However, RSI=71.3 and %B=1.04 indicate overbought conditions, and price sits only 0.9% below resistance at 207.68. Chasing here is poor risk/reward. The plan uses a limit entry on a pullback to the 200.50 support zone, validated by the web-derived 200.08 volatility-band support and the Aug 17 close at 200.95. Stop at 194.20 is below nearby structural support, and the first target at 213.50 is the next confirmed overhead resistance, giving roughly 2.1R. Earnings are on Oct 30, 2026, well outside the 10-day holding window, so gap risk from earnings is low.",
"risks": [
"Daily RSI is overbought and price is above the upper Bollinger Band, increasing pullback risk.",
"A break below the 200.08 support would invalidate the bull case and may accelerate selling.",
"The stock may not pull back to the 200.50 entry within 10 days, causing the trade to be missed.",
"Energy sector volatility and crude oil price swings could adversely affect CVX.",
"Broader market weakness or a rise in VIX could pressure the stock despite its strong chart."
],
"news_summary": "Verification via web search confirms strong bullish news: CVX posted a 287% jump in Q2 2026 adjusted earnings to $12 billion, achieved production records, and is positioned to benefit from Hess synergies. BlackRock also increased its stake. The next earnings report is scheduled around Oct 29-30, 2026, outside the 10-day holding window, so no imminent earnings gap risk. Sources: [cryptonomist.ch](https://en.cryptonomist.ch/2026/07/31/chevron-corporation-stock-surges-on-287-earnings-jump-eyes-199-breakout/), [tradersunion.com](https://tradersunion.com/news/stocks/show/3023859-chevron-gains-0-89percent-today-to/), [dragonflycap.com](https://dragonflycap.com/4-trade-ideas-for-chevron-bonus-idea-8/)."
}
XAGUSD BUY
Direction: BUY
Entry: $66.82 (limit)
Stop Loss: $65.10
Take Profit 1: $70.26 (+5.1%)
Take Profit 2: $71.50 (+7.0%)
R:R: 2.0
Position Size: 1.0% of account
Confidence: 0.6/100
Holding Period: 10 days
Key Levels
- Resistance: $67.46, $76.03
- Support: $63.12, $57.22
Rationale
Daily trend is bullish (Close > EMA50 > EMA21, Supertrend UP, ADX 27.6). The July NFP crash (-23K vs +80K est) and cooling CPI (2.25%) have driven a +10% weekly surge, and MacroAgentDesk remains bullish with a $70-75 target (macroagentdesk.com). FXTORCH notes the industrial bid persists despite the ratio break (fxtorch.com). Entry at 66.82 with a 1x ATR stop at 65.10 and a 2x ATR target at 70.26 satisfies the 2:1 reward/risk rule. A break above the 67.46 resistance could accelerate toward the target.
Risks
- Resistance at $67.46 may cap immediate upside and lead to a pullback.
- CMF (20) is negative (-0.36), indicating distribution pressure.
- Any hawkish Fed surprise or USD strength could reverse the rally.
- If price fails to hold above $65, a deeper retracement to $63.12 support is possible.
News Summary
July NFP fell -23K (first monthly decline since pre-2025), triggering a ~10% silver surge. July CPI at 2.25% (released Aug 12) supports Fed cut expectations. Silver is trading at $66.82, 21% below JP Morgan's $81 fair value. MacroAgentDesk sees continued rally toward $70-75 (macroagentdesk.com). FXTORCH points to persistent industrial demand (fxtorch.com).
{
"ticker": "SI=F",
"direction": "LONG",
"entry_price": 66.82,
"stop_loss": 65.1,
"take_profit_1": 70.26,
"take_profit_2": 71.5,
"reward_risk_ratio": 2.0,
"position_size_pct": 1.0,
"confidence": 0.6,
"holding_period_days": 10,
"key_levels": {
"support": [
63.12,
57.22
],
"resistance": [
67.46,
76.03
]
},
"rationale": "Daily trend is bullish (Close > EMA50 > EMA21, Supertrend UP, ADX 27.6). The July NFP crash (-23K vs +80K est) and cooling CPI (2.25%) have driven a +10% weekly surge, and MacroAgentDesk remains bullish with a $70-75 target ([macroagentdesk.com](https://www.macroagentdesk.com/motw-si-2026-08-09/)). FXTORCH notes the industrial bid persists despite the ratio break ([fxtorch.com](https://www.fxtorch.com/posts/2026/08/19/0130-silvers-63-handle-the-ratio-breaks-but-the-industrial-bid-remains/)). Entry at 66.82 with a 1x ATR stop at 65.10 and a 2x ATR target at 70.26 satisfies the 2:1 reward/risk rule. A break above the 67.46 resistance could accelerate toward the target.",
"risks": [
"Resistance at $67.46 may cap immediate upside and lead to a pullback.",
"CMF (20) is negative (-0.36), indicating distribution pressure.",
"Any hawkish Fed surprise or USD strength could reverse the rally.",
"If price fails to hold above $65, a deeper retracement to $63.12 support is possible."
],
"news_summary": "July NFP fell -23K (first monthly decline since pre-2025), triggering a ~10% silver surge. July CPI at 2.25% (released Aug 12) supports Fed cut expectations. Silver is trading at $66.82, 21% below JP Morgan's $81 fair value. MacroAgentDesk sees continued rally toward $70-75 ([macroagentdesk.com](https://www.macroagentdesk.com/motw-si-2026-08-09/)). FXTORCH points to persistent industrial demand ([fxtorch.com](https://www.fxtorch.com/posts/2026/08/19/0130-silvers-63-handle-the-ratio-breaks-but-the-industrial-bid-remains/))."
}
ADBE BUY
Direction: BUY
Entry: $263.50 (limit)
Stop Loss: $253.50
Take Profit 1: $283.50 (+7.6%)
Take Profit 2: $291.00 (+10.4%)
R:R: 2.0
Position Size: 1.5% of account
Confidence: 55/100
Holding Period: 10 days
Key Levels
- Resistance: $275.80, $284.20
- Support: $263.14, $254.04, $250.84
Rationale
Bullish bias from price above 200 SMA and all EMAs, Supertrend up, positive CMF, and earnings outside the 10-day window. Buy limit at 263.50 near EMA21/recent support with stop below 254.04; TP1 at 283.50 gives at least 2:1 R/R, with TP2 at 291.00 on momentum extension. Setup triggers only on pullback; if invalidated, no trade.
Risks
- 1H StochRSI is overbought at 88/93, raising risk of a deeper pullback before entry fills.
- Daily ADX 22.7 and negative MACD histogram indicate mixed/developing trend, not strong momentum.
- Resistance at 275.80–284.20 may cap near-term upside.
- High volatility (ATR 11.88, 4.36%) increases whipsaw risk around stops.
- If limit entry at 263.50 is not filled, the plan produces no position.
News Summary
Earnings confirmed 2026-09-10, outside 10-day window. Recent news highlights Adobe's record FY25 revenue ($23.77B), a free ChatGPT plugin for Photoshop/Premiere, and a BlackRock stake increase, though analyst caution and prior CFO-departure concerns remain. Resistance at ~$285 per tradingdashboard.com; mixed sentiment noted by jasonwheel.com.
{
"ticker": "ADBE",
"direction": "LONG",
"entry_price": 263.5,
"stop_loss": 253.5,
"take_profit_1": 283.5,
"take_profit_2": 291.0,
"reward_risk_ratio": 2.0,
"position_size_pct": 1.5,
"confidence": 55,
"holding_period_days": 10,
"key_levels": {
"support": [
263.14,
254.04,
250.84
],
"resistance": [
275.8,
284.2
]
},
"rationale": "Bullish bias from price above 200 SMA and all EMAs, Supertrend up, positive CMF, and earnings outside the 10-day window. Buy limit at 263.50 near EMA21/recent support with stop below 254.04; TP1 at 283.50 gives at least 2:1 R/R, with TP2 at 291.00 on momentum extension. Setup triggers only on pullback; if invalidated, no trade.",
"risks": [
"1H StochRSI is overbought at 88/93, raising risk of a deeper pullback before entry fills.",
"Daily ADX 22.7 and negative MACD histogram indicate mixed/developing trend, not strong momentum.",
"Resistance at 275.80–284.20 may cap near-term upside.",
"High volatility (ATR 11.88, 4.36%) increases whipsaw risk around stops.",
"If limit entry at 263.50 is not filled, the plan produces no position."
],
"news_summary": "Earnings confirmed 2026-09-10, outside 10-day window. Recent news highlights Adobe's record FY25 revenue ($23.77B), a free ChatGPT plugin for Photoshop/Premiere, and a BlackRock stake increase, though analyst caution and prior CFO-departure concerns remain. Resistance at ~$285 per [tradingdashboard.com](https://tradingdashboard.com/en/stocks/ADBE-NASDAQ); mixed sentiment noted by [jasonwheel.com](https://www.jasonwheel.com/?ticker=ADBE)."
}